BioCentury
ARTICLE | Company News

Ethypharm, Lansen Pharmaceutical sales and marketing update

October 31, 2011 7:00 AM UTC

Ethypharm granted Lansen's Ningbo Lansen Pharmaceutical Co. Ltd. subsidiary exclusive rights to commercialize ketoprofen/omeprazole in China. Ethypharm will be responsible for developing the compound and obtaining an Import Drug License from the China's State Food and Drug Administration. Lansen will be responsible for repackaging the drug. Lansen said the drug would be approved in four to six years. Terms were not disclosed. ...